SUBSCRIBE
2 minutes
Edinburgh-based immune-oncology firm Macomics has secured £3.2 million seed funding from Epidarex Capital and the Scottish Investment Bank. Macomics, which is a University of Edinburgh spin-out, will use the proceeds of this fundraising round to develop novel, first-in-class immunotherapies de
